Hostname: page-component-76fb5796d-2lccl Total loading time: 0 Render date: 2024-04-25T11:46:09.931Z Has data issue: false hasContentIssue false
  • English
  • Français

The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation

Published online by Cambridge University Press:  06 August 2018

Stanley R. Kay ,
Lewis A. Opler  and
Jean-Pierre Lindenmayer
Stanley R. Kay*
Affiliation:
Department of Psychiatry, Albert Einstein College of Medicine/Montefiore Medical Center and Bronx Psychiatric Centre, New York
Lewis A. Opler
Affiliation:
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, and Presbyterian Hospital, New York
Jean-Pierre Lindenmayer
Affiliation:
Department of Psychiatry, Albert Einstein College of Medicine/Montefiore Medical Center and Bronx Psychiatric Centre, New York
*
∗Schizophrenia Research Program, Bronx Psychiatric Center, 1500 Waters Place, Bronx, NY 10461, USA
Get access Rights & Permissions [Opens in a new window]

Extract

Over 75 years ago, Bleuler (1911) confronted psychiatry with the question of ‘schizophrenia’ or ‘schizophrenias'. Today we recognise the heterogeneity of the condition, but we are still groping at efforts to clarify the different subtypes or subprocesses. Over the decades there have been various attempts to subclassify schizophrenia and tease apart the syndromes, none of which has been entirely successful. More recently, as a result of the work by Crow (1980) in England and Strauss et al (1974) in the USA, it has been proposed that two distinct syndromes can be discerned from the phenomenological profiles. The positive syndrome consists of productive features superadded to the mental status, such as delusions, hallucinations, and disorganised thinking. The negative syndrome represents absence of normal functions, such as deficits in the cognitive, affective, and social realms.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 155 , Issue S7: Negative Symptoms in Schizophrenia , November 1989 , pp. 59 - 65
Copyright
Copyright © Royal College of Psychiatrists, 1989 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, N.C. (1982) Negative symptoms in schizophrenia: Definition and reliability. Archives of General Psychiatry, 39, 784–788.CrossRefGoogle ScholarPubMed
Angrist, B., Rotrosen, J. & Gershon, S. (1980) Differential effects of amphetamine and neuroleptics on negative vs positive symptoms in schizophrenia. Psychopharmacologia, 72, 17–19.CrossRefGoogle ScholarPubMed
Bilder, R.M., Mukherjee, S., Rieder, R.O., et al (1985) Symptomatic and neuropsychological components of defect states. Schizophrenia Bulletin, 11, 409–419.CrossRefGoogle ScholarPubMed
Bishop, R.J., Golden, C.J., MacInnes, W.D., et al (1983) The BPRS in assessing symptom correlates of cerebral ventricular enlargement in acute and chronic schizophrenia. Psychiatry Research, 9, 225–231.CrossRefGoogle ScholarPubMed
Bleuler, E. (1911) Dementia Praecox or the Group of Schizophrenias. Translated by J. Zinkin (1950). New York: International Universities Press.Google Scholar
Carpenter, W.T. Jr., Heinrichs, D.W. & Alphs, L.D. (1985) Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440–452.CrossRefGoogle ScholarPubMed
Cornblatt, B.A., Lenzenweger, M.F., Dworkin, R.H., et al (1985) Positive and negative schizophrenic symptoms, attention, and information processing. Schizophrenia Bulletin, 11, 397–408.CrossRefGoogle ScholarPubMed
Crow, T.J. (1980) Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry, 137, 383–386.CrossRefGoogle ScholarPubMed
Falloon, I., Watt, D.C. & Shepherd, M. (1978) The social outcome of patients in a trial of long-term continuation therapy in schizophrenia: Pimozide vs fluphenazine. Psychological Medicine, 8, 265–274.CrossRefGoogle Scholar
Feinberg, S.S., Kay, S.R., Elijovich, L.R., et al (1988) Pimozide treatment of the negative schizophrenic syndrome: An open trial. Journal of Clinical Psychiatry, 49, 235–238.Google ScholarPubMed
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare.Google Scholar
Iager, A.-C., Kirch, D.C. & Wyatt, R.J. (1985) A negative symptom rating scale. Psychiatry Research, 166, 27–36.CrossRefGoogle Scholar
Kay, S.R. (1981) Arousal and schizophrenia: Toward a dual-process model and framework for research. JSAS Catalog of Selected Documents in Psychology, 11, Whole No. 2256.Google Scholar
Kay, S.R. & Lindenmayer, J.-P. (1987) Outcome predictors in acute schizophrenia: Prospective significance of background and clinical dimensions. Journal of Nervous and Mental Disease, 175, 152–160.Google Scholar
Kay, S.R. & Opler, L.A. (1985) L-DOPA in the treatment of negative schizophrenic symptoms: A single-subject experimental study. International Journal of Psychiatry in Medicine, 15, 293–298.CrossRefGoogle ScholarPubMed
Kay, S.R. & Opler, L.A. (1987) The positive-negative dimension in schizophrenia: Its validity and significance. Psychiatric Developments, 5, 79–103.Google ScholarPubMed
Kay, S.R., Opler, L.A. & Fiszbein, A. (1985) Genetics of schizophrenia and the positive—negative dimension. American Journal of Psychiatry, 142, 994–995.CrossRefGoogle ScholarPubMed
Kay, S.R., Fiszbein, A., Lindenmayer, J.-P., et al (1986a) Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatrica Scandinavica, 74, 507–518.CrossRefGoogle ScholarPubMed
Kay, S.R., Fiszbein, A. & Opler, L.A. (1986b) Negative symptom rating scale: Limitations in psychometric and research methodology. Psychiatry Research, 19, 169–170.Google Scholar
Kay, S.R., Opler, L.A. & Fiszbein, A. (1986c) Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry, 149, 439–448.CrossRefGoogle ScholarPubMed
Kay, S.R., Fiszbein, A. & Opler, L.A. (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.CrossRefGoogle ScholarPubMed
Kay, S.R., Opler, L.A. & Lindenmayer, J.-P. (1988) Reliability and validity of the Positive and Negative Syndrome Scale for Kay, S.R., schizophrenics. Psychiatry Research, 23, 99–110.CrossRefGoogle ScholarPubMed
Lindenmayer, J.-P., Kay, S.R. & Opler, L.A. (1984) Positive and negative subtypes in acute schizophrenia. Comprehensive Psychiatry, 25, 455–464.Google Scholar
Lindenmayer, J.-P., Kay, S.R. & Friedman, C. (1986) Negative and positive schizophrenic syndromes after the acute phase: A prospective follow-up. Comprehensive Psychiatry, 27, 276–286.CrossRefGoogle ScholarPubMed
Opler, L.A. & Kay, S.R. (1985) Birth seasonality and schizophrenia. Archives of General Psychiatry, 42, 107.CrossRefGoogle Scholar
Opler, L.A., Kay, S.R., Rosado, V. et al (1984) Positive and negative syndromes in chronic schizophrenic inpatients. Journal of Nervous and Mental Disease, 172, 317–325.Google Scholar
Opler, L.A., Kay, S.R. & Fiszbein, A. (1987) Positive and negative syndromes in schizophrenia: Typological, dimensional, and pharmacological validation. In Positive and Negative Symptoms in Psychosis: Description, Research, and Future Directions in Positive and Negative Symptoms in Psychosis: Description, Research, and Future Directions (eds Harvey, P.D. & Walker, E.), pp. 124–154. Hillside, NJ: Erlbaum.Google Scholar
Overall, J.E. & Gorham, D.R. (1962) Brief psychiatric rating scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Pinder, R.M., Brogden, R.M. & Sawyer, P.R. (1976) Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs, 12, 1–40.CrossRefGoogle ScholarPubMed
Rosen, W.G., Mohs, R.C., Johns, C.A., et al (1984) Positive and negative symptoms in schizophrenia. Psychiatry Research, 13, 277–284.Google Scholar
Singh, M.M. & Kay, S.R. (1975) A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: Theoretical implications for potency differences among neuroleptics. Psychopharmacologia, 43, 103–113.Google Scholar
Singh, M.M., Kay, S.R. & Opler, L.A. (1987) Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: Implications for psychobiological subtyping. Psychological Medicine, 17, 39–48.Google Scholar
Sommers, A.A. (1985) ‘Negative symptoms': Conceptual and methodological problems. Schizophrenia Bulletin, 11, 364–379.CrossRefGoogle ScholarPubMed
Strauss, J.S. & Carpenter, W.T. (1974) The prediction of outcome in schizophrenia: II. Relationship between predictors and outcome variables. Archives of General Psychiatry, 31, 37–42.CrossRefGoogle ScholarPubMed
Strauss, J.S., Carpenter, W.T. & Bartko, J.J. (1974) The diagnosis and understanding of schizophrenia: II. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophrenia Bulletin, 11, 61–76.Google Scholar
Zubin, J. (1985) Negative symptoms: Are they indigenous to schizophrenia? Schizophrenia Bulletin, 11, 461–470.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.